Subscribe to Breaking World Pharma News’s news feed.
Click on “Follow” and decide if you want to get news from Breaking World Pharma News via RSS, as email newsletter, via mobile or on your personal news page.
Subscription to Breaking World Pharma News comes without risk as you can unsubscribe instantly at any time.
You can also filter the feed to your needs via topics and keywords so that you only receive the news from Breaking World Pharma News which you are really interested in. Click on the blue “Filter” button below to get started.
Title: Breaking World Pharma News
Is this your feed? Claim it!
Researchers from IRTA and IrsiCaixa, partners in the EPIVINF project, have identified the golden Syrian hamster as a potential relevant model for studying the biology of long COVID, also known as post-COVID-19 condition (PCC).
Long COVID is not a single disease but a complex syndrome involving a range of persistent symptoms. People suffering from it report overwhelming fatig...
Plants make substances called alkaloids to protect themselves, and humans have long taken advantage of these chemicals, using them in painkillers, treatments for disease and household products such as caffeine and nicotine.
By understanding how plants make these substances, researchers aim to produce new and improved chemicals for medicines more quickly, cheaply and with les...
The mucosal surfaces that line the body are embedded with defensive molecules that help keep microbes from causing inflammation and infections. Among these molecules are lectins - proteins that recognize microbes and other cells by binding to sugars found on cell surfaces.
One of these lectins, MIT researchers have found, has broad-spectrum antimicrobial activity against bac...
Researchers at McMaster University are leading preclinical studies into a novel drug candidate developed by Espervita Therapeutics that has the potential to prevent and reverse liver fibrosis - a dangerous, disease-induced build-up of scar tissue in the liver that often leads to cancer.
The findings point to a potential new treatment for the millions of people living with li...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced the successful completion of the cash tender offer, through a subsidiary, for all the outstanding shares of common stock of Cidara Therapeutics, Inc. (Nasdaq: CDTX) (“Cidara”).
